FDA Approves Remicade for Psoriatic Arthritis

The U.S. Food and Drug Administration (FDA) has approved Remicade (infliximab) to reduce the signs and symptoms of active arthritis in patients with psoriatic arthritis. Read the press release for more information. The latest approval marks the ninth time the FDA has approved a new indication for Remicade.

Related Resources:

• The Facts of Remicade
• Remicade, Humira, and Enbrel: How Are They Similar and Different?
• Psoriatic Arthritis Screening Quiz
• Fast Facts About Psoriatic Arthritis
• Psoriatic Arthritis: Test Your Knowledge
• Primary Symptoms of Psoriatic Arthritis
• Psoriatic Arthritis and Rheumatoid Arthritis - What's the Difference?